Literature DB >> 16216545

Diagnosis of NASH using delayed parenchymal imaging of contrast ultrasound.

Fuminori Moriyasu1, Hiroko Iijima, Kaoru Tsuchiya, Yuki Miyata, Akihiro Furusaka, Takeo Miyahara.   

Abstract

BACKGROUND AND AIMS: Non alcoholic steatohepatitis (NASH) is one of the representative liver diseases in the developed countries. Diagnosis of NASH is dependent on histological findings from liver biopsy. Usefulness of contrast ultrasound with Levovist for diagnosis of NASH is described. METHODS AND MATERIALS: Clinical study: Ultrasound contrast agent, Levovist of 2.5g was injected intravenously. The liver was scanned at 5, 10, 15, 20, 30, 40, and 50min after Levovist injection in different planes using a contrast specific ultrasound mode. Changes in microbubble accumulation in the liver were evaluated. The signal intensity from regions of interest (ROI) on the contrast images was measured and accumulation and decrescence of microbubbles were estimated using the time intensity curves (TICs). The image data and TICs were evaluated by blind reviewers. Fifteen patients with NASH, 8 with alcoholic steatohepatitis (ASH), 45 with non alcoholic fatty liver (NAFL), 10 with chronic hepatitis C (CHC) and 10 healthy volunteers were studied. Animal study: Methionine-choline-deficient diet (MCDD) fed rats were used for NASH model. Correlation between microbubble accumulation and morphological and functional changes of sinusoidal endothelium and macrophage was evaluated.
RESULTS: The maximum intensity of contrast ultrasound was decreased and time course decrescence was more rapid in NASH than the other groups. These changes were correlated to the degree of centrilobular and pericellular fibrosis but not to steatosis in histological study. Disturbance of microbubble accumulation was correlated with sinusoidal function rather than morphological changes such as fibrosis and parenchymatitis in the animal studies.
CONCLUSIONS: The Levovist contrast study enables differential diagnosis between NASH and other diseases that provoke steatosis and fibrosis.

Entities:  

Year:  2005        PMID: 16216545     DOI: 10.1016/j.hepres.2005.09.013

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  7 in total

1.  Decreased accumulation of ultrasound contrast in the liver of nonalcoholic steatohepatitis rat model.

Authors:  Yuki Miyata; Takeo Miyahara; Fuminori Moriyasu
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

2.  Contrast-enhanced US of ampullary carcinoma: correlations with pathological findings.

Authors:  Nobuyuki Kiura; Shozo Okamura; Fumihiro Urano; Kazuhiro Hiramatsu; Matsuyoshi Maeda; Takuya Ishikawa; Hidemi Goto; Yoshiki Hirooka
Journal:  J Med Ultrason (2001)       Date:  2012-02-21       Impact factor: 1.314

3.  Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan.

Authors:  Yoshio Sumida; Yuichiro Eguchi; Masafumi Ono
Journal:  World J Hepatol       Date:  2010-10-27

4.  Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease.

Authors:  Benjamin Pulli; Gregory Wojtkiewicz; Yoshiko Iwamoto; Muhammad Ali; Matthias W Zeller; Lionel Bure; Cuihua Wang; Yuri Choi; Ricard Masia; Alex R Guimaraes; Kathleen E Corey; John W Chen
Journal:  Radiology       Date:  2017-03-30       Impact factor: 11.105

5.  Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model.

Authors:  Tatsuhiro Tsujimoto; Hideto Kawaratani; Toshiyuki Kitazawa; Toshiko Hirai; Hajime Ohishi; Mitsuteru Kitade; Hitoshi Yoshiji; Masahito Uemura; Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

Review 6.  Nonalcoholic fatty liver disease in children living in the obeseogenic society.

Authors:  H Hesham A-Kader
Journal:  World J Pediatr       Date:  2009-11-13       Impact factor: 2.764

Review 7.  Studies on oxidative stress in liver diseases: important future trends in liver research.

Authors:  Kyuichi Tanikawa; Takuji Torimura
Journal:  Med Mol Morphol       Date:  2006-03       Impact factor: 2.070

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.